AVS Bio, an Arlington Capital Partners Portfolio Company, Expands Antibody Discovery and Protein Production Capabilities With Acquisition of ImmunoPrecise Antibodies Europe From ImmunoPrecise Antibodies Ltd. - Candlesense

AVS Bio, an Arlington Capital Partners Portfolio Company, Expands Antibody Discovery and Protein Production Capabilities With Acquisition of ImmunoPrecise Antibodies Europe From ImmunoPrecise Antibodies Ltd.

WASHINGTON & NORWICH, Conn.--(BUSINESS WIRE)--Arlington Capital Partners (ā€œArlingtonā€), a Washington, D.C.-area private investment firm specializing in government regulated industries, today announced that its portfolio company AVS Bio, a leading global provider of critical inputs and services for the bioprocessing and biologics industries, acquired ImmunoPrecise Antibodies (Europe) B.V. (ā€œIPA Europeā€ or the ā€œCompanyā€). IPA Europe is a carve-out of ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA), a